Rani Therapeutics Holdings (RANI) Price & Analysis

Compare

1,450 Followers

RANI Stock Chart & Stats

$2.50

-$0.04(-3.15%)

At close: Jan 08 4:00 PM EST

$2.50

-$0.04(-3.15%)

Day’s Range― - ―

52-Week Range$0.39 - $3.87

Previous CloseN/A

Volume228.85K

Average Volume (3M)34.72M

Market Cap

$171.05M

Enterprise Value$26.10M

Total Cash (Recent Filing)$10.22M

Total Debt (Recent Filing)$19.39M

Price to Earnings (P/E)―

Beta1.45

Next Earnings

Nov 12, 2025

EPS Estimate

-0.15

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.18

Shares Outstanding47,898,228

10 Day Avg. Volume24,750,591

30 Day Avg. Volume34,720,480

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.15

Enterprise Value/Revenue21.75

Enterprise Value/Gross Profit37.24

Enterprise Value/Ebitda-0.54

Forecast

1Y Price Target

$10.00

Price Target Upside300.00% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering3

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Financial PerformanceWith the additional capital expected to provide sufficient funding into 2028, RANI is now positioned to advance its lead obesity program, RT-114 into the clinic for obese, non-diabetic patients.

Market ValidationThe Chugai collaboration validates the RANI platform in our view.

Strategic PartnershipsRani Therapeutics announced a licensing deal for RaniPill technology to Chugai Pharmaceutical, with a concurrent private placement among fundamental healthcare institutions raising $60M in proceeds.

Bears Say

Rani Therapeutics Holdings News

Rani Therapeutics reports Q3 EPS (12c), consensus (12c)

Cash, cash equivalents and marketable securities as of September 30 totaled $4.1M, compared to $27.6M for the year...

2h ago

RANI

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: Kodiak AI, Inc. Common...

3d ago

ABR

KDK

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: Beyond Meat (BYND) 46.53%...

8d ago

BTQ

SLS

3 Penny Stocks to Watch Now, 10/22/25

Beyond Meat, Rani Therapeutics, and VSee Health are the 3 Penny Stocks to watch on October 22, 2025,...

15d ago

WMT

BYND

Unusually active option classes on open October 21st

Unusual total active option classes on open include: Beyond Meat (BYND), Rani Therapeutics Holdings (RANI), 3M (MMM), Coca...

16d ago

Rani Therapeutics assumed with a Buy at H.C. Wainwright

H.C. Wainwright analyst Brandon Folkes assumed coverage of Rani Therapeutics (RANI) with a Buy rating and $11 price...

17d ago

RANI

Rani Therapeutics price target raised to $10 from $5 at Maxim

Maxim raised the firm’s price target on Rani Therapeutics (RANI) to $10 from $5 and keeps a Buy...

17d ago

RANI

Why This Penny Biotech Stock Is Still Climbing After a 250% Surge

Rani Therapeutics Holdings ($RANI), a clinical-stage penny biotech stock, soared nearly 250% on Friday and continued to trade...

17d ago

RANI

Morning News Wrap-Up: Friday’s Biggest Stock Market Stories!

It’s the final day of trading this week and TipRanks has collected all of the hottest stock market news for Friday. ...

19d ago

Why Is Rani Therapeutics Stock Up 150% Today?

Rani Therapeutics stock soared after the company provided details on an oversubscribed private placement. ...

20d ago

RANI

Rani Therapeutics prices 42.6M shares at 48c in private placement

Rani Therapeutics (RANI) entered into a securities purchase agreement with certain institutional and accredited investors, with participation by...

21d ago

RANI

Rani Therapeutics announces debt conversion

In connection with the private placement, Avenue Venture Opportunities Fund will convert $6M of outstanding debt into 12,500,000...

21d ago

RANI

Rani Therapeutics announces $1.085B collaboration with Chugai Pharmaceutical

Rani Therapeutics (RANI) entered into a Collaboration and License Agreement with Chugai Pharmaceutical (CHGCY) for the development and...

21d ago

RANI

Rani Therapeutics Launches Phase 1 Study for Obesity Treatment RT-114

Rani Therapeutics Holdings, Inc. Class A (($RANI)) announced an update on their ongoing clinical study. Rani Therapeutics Holdings,...

10d ago

RANI

RANI FAQ

What was Rani Therapeutics Holdings’s price range in the past 12 months?

Rani Therapeutics Holdings lowest stock price was $0.39 and its highest was $3.87 in the past 12 months.

What is Rani Therapeutics Holdings’s market cap?

Rani Therapeutics Holdings’s market cap is $171.05M.

When is Rani Therapeutics Holdings’s upcoming earnings report date?

Rani Therapeutics Holdings’s upcoming earnings report date is Nov 12, 2025 which is in 5 days.

How were Rani Therapeutics Holdings’s earnings last quarter?

Rani Therapeutics Holdings released its earnings results on Aug 07, 2025. The company reported -$0.18 earnings per share for the quarter, beating the consensus estimate of -$0.285 by $0.105.

Is Rani Therapeutics Holdings overvalued?

According to Wall Street analysts Rani Therapeutics Holdings’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Rani Therapeutics Holdings pay dividends?

Rani Therapeutics Holdings does not currently pay dividends.

What is Rani Therapeutics Holdings’s EPS estimate?

Rani Therapeutics Holdings’s EPS estimate is -0.15.

How many shares outstanding does Rani Therapeutics Holdings have?

Rani Therapeutics Holdings has 47,898,228 shares outstanding.

What happened to Rani Therapeutics Holdings’s price movement after its last earnings report?

Rani Therapeutics Holdings reported an EPS of -$0.18 in its last earnings report, beating expectations of -$0.285. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Rani Therapeutics Holdings?

Currently, no hedge funds are holding shares in RANI

Rani Therapeutics Holdings Stock Smart Score

Outperform

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

-61.35%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Rani Therapeutics Holdings

Rani Therapeutics Holdings (RANI) is a healthcare company focused on developing innovative oral biologics utilizing its proprietary RaniPill technology. The company operates within the biotechnology and pharmaceutical sectors, offering a unique solution for the oral delivery of biologics, which are traditionally administered via injection. Rani's core product, the RaniPill capsule, is designed to deliver large-molecule drugs through the gastrointestinal tract, thereby improving patient compliance and expanding the potential market for biologic therapies.

Rani Therapeutics Holdings (RANI) Earnings & Revenues

Historic Earnings Reports

RANI Stock 12 Month Forecast

Average Price Target

$10.00

▲(300.00% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"12":"$12","-1":"-$1","2.25":"$2.25","5.5":"$5.5","8.75":"$8.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":11,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$11.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$10.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":9,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$9.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,2.25,5.5,8.75,12],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.51,1.3169230769230769,2.123846153846154,2.930769230769231,3.737692307692308,4.544615384615384,5.351538461538461,6.158461538461538,6.9653846153846155,7.772307692307693,8.579230769230769,9.386153846153846,10.193076923076923,{"y":11,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.51,1.24,1.97,2.7,3.4299999999999997,4.16,4.89,5.619999999999999,6.35,7.08,7.81,8.54,9.27,{"y":10,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.51,1.1630769230769231,1.8161538461538462,2.4692307692307693,3.1223076923076922,3.775384615384615,4.428461538461539,5.081538461538462,5.734615384615385,6.387692307692308,7.0407692307692304,7.693846153846154,8.346923076923078,{"y":9,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.69,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.37,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.5,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.72,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.31,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.31,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.37,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.39,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.53,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.23,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.07,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.51,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.51,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >